US OptionsDetailed Quotes

ALEC241220C5000

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.05High0.05Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Nov 25 15:06
    NEWS
    $Alector (ALEC.US)$
    Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
    Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefit...
    Jaguar8
    Jaguar8
    Sep 19 07:24
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...
    Jaguar8
    Jaguar8
    Jul 28 07:06
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
    Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
    The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
    Key point...
    Moomoo AI
    Moomoo AI
    Jan 19 13:58
    Alector's low P/S ratio may be due to poor revenue performance and expectations of this trend continuing. Future revenue growth is expected to be significantly lower than the industry, possibly causing discomfort among shareholders and a drop in share price.
    Little Excitement Around Alector, Inc.'s (NASDAQ:ALEC) Revenues As Shares Take 27% Pounding
Read more